Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
soluble TGFβ type III receptor
- Development stage
- Preclinical
- Lead developer
- University of Kentucky
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intraperitoneal, Intratumoral
01
Overview
Soluble TGFβ type III receptor (also known as soluble betaglycan or sRIII) is a recombinant soluble protein consisting of the extracellular domain of the transforming growth factor-beta (TGF-β) type III receptor. It acts as a high-affinity decoy receptor (ligand trap) that selectively binds and sequesters TGF-β isoforms, particularly TGF-β1, TGF-β2, and TGF-β3, thereby preventing them from interacting with their signaling receptors (TGFBR1 and TGFBR2). Preclinical studies have demonstrated that soluble TGFβ type III receptor can suppress tumor growth, angiogenesis, and metastasis in various cancer models, including breast cancer and breast cancer-induced osteolytic bone metastasis, by antagonizing the tumor-promoting activities of autocrine and paracrine TGF-β.
- Other names
- recombinant soluble betaglycanrecombinant soluble TGFβ type III receptorsBGsRIIIsTGFBR3sTGFBR-3sTGFBR 3soluble betaglycansoluble TGF-beta receptor type IIIsoluble TGF-beta type III receptorsoluble TGFβ receptor type III
02
Targets
TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB2 (Transforming growth factor beta 2)TGFB3 (Transforming growth factor beta 3)BMP (Bone morphogenetic protein family)
Beyond the preview
Go deeper on soluble TGFβ type III receptor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on soluble TGFβ type III receptor.